Skip to Main content Skip to Navigation
Theses

Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia

Abstract : CD20 is a validated target for the immunotherapy of B lymphoid neoplasms, including ChronicLymphocytic Leukemia (CLL). We compared the activities of rituximab and GA101 (novel anti-CD20 antibody)on fresh human CLL cells in vitro. AnnexinV staining demonstrated induction of apoptosis after exposure torituximab or GA101. Unlike rituximab, GA101 induced a reduction of the mitochondrial transmembranepotential, an effect which could be partially inhibited by cyclosporin A and which was partially caspasedependent.GA101 was also found to induce the production of Reactive Oxygen Species. Analysis of pro- andanti-apoptotic protein content after exposure to antibodies demonstrated a strong degree of heterogeneity between samples. Bax underwent conformational activation and mitochondrial translocation upon exposure toantibodies in a caspase-independent manner. GA101 but not rituximab induced cleavage of caspase-8, -9 and -3.By transfecting CLL cells with anti-Bcl-xL siRNA using a sonoporation method, we found that reduction of BclxLcontent was associated with increased sensitivity to these antibodies. Our results suggest that apoptoticsignalization pathways differ between rituximab and GA101 with a greater involvement of the mitochondrialpathway for GA101. Inhibition of Bcl-xL could constitute an approach to sensitize CLL cells to the apoptoticeffects of anti-CD20 antibodies.
Complete list of metadatas

Cited literature [188 references]  Display  Hide  Download

https://tel.archives-ouvertes.fr/tel-00863639
Contributor : Abes Star :  Contact
Submitted on : Thursday, September 19, 2013 - 12:03:15 PM
Last modification on : Wednesday, November 20, 2019 - 3:15:21 AM
Document(s) archivé(s) le : Friday, December 20, 2013 - 3:12:45 PM

File

TH2010_Reslan_-_Lina_-_art_-_c...
Version validated by the jury (STAR)

Identifiers

  • HAL Id : tel-00863639, version 1

Collections

Citation

Lina Reslan. Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia. Human health and pathology. Université Claude Bernard - Lyon I, 2010. English. ⟨NNT : 2010LYO10346⟩. ⟨tel-00863639⟩

Share

Metrics

Record views

828

Files downloads

1762